Scarica l'app Stockscreener
85.48
1.62%
1.36
Pre-mercato:
85.50
0.02
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$84.12
Aprire:
$84.5
Volume 24 ore:
11.64M
Relative Volume:
0.85
Capitalizzazione di mercato:
$213.51B
Reddito:
$63.43B
Utile/perdita netta:
$16.42B
Rapporto P/E:
13.17
EPS:
6.49
Flusso di cassa netto:
$14.72B
1 W Prestazione:
+0.58%
1M Prestazione:
+7.81%
6M Prestazione:
-7.34%
1 anno Prestazione:
-27.83%
Intervallo 1D:
$84.34
$85.50
Intervallo di 1 settimana:
$82.65
$85.50
Portata 52W:
$73.31
$120.30
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Confronta MRK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
85.48 | 210.11B | 63.43B | 16.42B | 14.72B | 6.49 |
|
LLY
Lilly Eli Co
|
735.19 | 656.73B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 426.69B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
211.92 | 371.68B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.64 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Veterinary Oncology Market Shares, Competition and Trends Analysis 2025-2030: Discover the Impact of Advanced Therapies and Digital Tools - GlobeNewswire Inc.
Merck Taps US Investment-Grade Bond Market for Verona Purchase - Bloomberg.com
Merck's cholesterol drug gets a boost with another late-stage trial success - Reuters
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK) - Benzinga
Merck's Portfolio and Solid Late-Stage Pipeline Defend Against Upcoming Keytruda Headwinds - Morningstar
Leerink Partners Remains Bullish on Merck & Co. (MRK) - MSN
No Spoils For VICTOR As Bayer/Merck & Co’s Verquvo Fails Phase III Trial - insights.citeline.com
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - PharmiWeb.com
Merck succeeds in late-stage trial for cholesterol drug - Seeking Alpha
First-Ever Oral PCSK9 Drug Success: Merck's Enlicitide Shows Breakthrough in Cholesterol Treatment - Stock Titan
Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028 - Yahoo Finance
Merck & Co. Inc. (MRK) Initiates Phase 3 Trial on Breast Cancer Drug - MSN
Animal Health Market Trends, Key Player Strategies, and Growth Outlook to 2034 - GlobeNewswire Inc.
Co. Inc.Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial - Yahoo Finance
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction - FinancialContent
Is Merck Stock Outperforming the Dow? - MSN
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Merck to Participate in the 2025 Wells Fargo Healthcare Conference - PharmiWeb.com
Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances - Insider Monkey
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% in Q2 2025 - AInvest
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% - Yahoo Finance
Summit, Akeso Lung Cancer Drug Rivals Merck’s KeytrudaSummit Therapeutics (NASDAQ:SMMT) - Benzinga
Rising as One, Shining as Many - GlobeNewswire Inc.
Merck & Co., Inc. shares fall 1.73% intraday after Bernstein reiterates Neutral rating, lowering target price to EUR 138. - AInvest
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025 - The Globe and Mail
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck shares snapped six-session winning streak (NYSE:MRK) - Seeking Alpha
Merck & Co Inc (MRK) Highlights Gaps in Flea and Tick Prevention Adherence - AInvest
Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal - BioWorld MedTech
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds - Business Wire
Merck & Co., Inc. shares rise 1.71% intraday after FDA grants Breakthrough Therapy Designation to Ifinatamab Deruxtecan for small cell lung cancer. - AInvest
Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal - insights.citeline.com
Merck KGaA Signs $2 Billion Neurology Drug Pact With Skyhawk - Bloomberg.com
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target - Seeking Alpha
Q3 EPS Estimates for Merck & Co., Inc. Cut by Zacks Research - Defense World
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - MSN
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial - MSN
Merck Stock: Buy The Weakness (NYSE:MRK) - Seeking Alpha
Austria Accepts Merck Commitments After ‘Predatory Pricing’ Undermined Generics - insights.citeline.com
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness - MSN
The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey - Yahoo Finance
Top Analyst Reports for Merck, Palo Alto & Freeport - Yahoo Finance
10 Stocks Jim Cramer Discussed As He Questioned Official Data - Insider Monkey
Livestock Monitoring Company Evaluation Report 2025 | Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation - Yahoo Finance
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):